Abstract 5655
Background
Napabucasin (2-acetylfuro-1,4-naphthoquinone) is a small molecule currently being clinically evaluated in several different cancer types. It has mostly been recognized for its ability to inhibit STAT3-mediated gene expression with activity against bulk tumor cells, as well as cancer stem cells. However, based on its chemical structure, we hypothesized that napabucasin is a substrate for reduction by NAD(P)H:quinone oxidoreductase-1 (NQO1) and therefore may exert its anti-cancer effect through redox cycling, resulting in reactive oxygen species (ROS) production and cell death.
Methods
Binding of napabucasin to NQO1, as well as other oxidoreductases, was measured. Pancreatic cancer cell lines and xenografts were treated with napabucasin, and cell survival, ROS generation, glutathione to glutathione disulfide (GSH:GSSG) ratios and changes in STAT3 signaling were assayed. Genetic knockout or pharmacological inhibition with dicoumarol was used to evaluate the dependency on NQO1 in vitro and in vivo.
Results
Napabucasin was found to bind with high affinity to NQO1 and to a lesser degree to cytochrome P450 oxidoreductase (POR). Differential cytotoxic effects were observed, where NQO1-expressing cells in particular were highly sensitive. Treatment resulted in significant induction of ROS with reduced GSH:GSSG ratios, increased DNA damage and an NQO1-dependent decrease in STAT3 phosphorylation. Cells with low or no baseline NQO1 expression also produced ROS in response to napabucasin treatment, albeit to a lesser degree, through the one-electron reductase POR.
Conclusions
Napabucasin is bioactivated by oxidoreductases, in particular NQO1 and to a lesser extent POR, resulting in futile redox cycling and generation of cytotoxic levels of ROS. The increase in ROS has multiple intracellular effects, one of which is a reduction in STAT3 signaling, ultimately resulting in cell death.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Lustgarten Foundation, National Institutes of Health, Donaldson Charitable Trust, Boston Biomedical Inc.
Disclosure
J. Li: Full / Part-time employment: Boston Biomedical, Inc. A. Chang: Full / Part-time employment: Boston Biomedical, Inc.. H.A. Rogoff: Full / Part-time employment: Boston Biomedical, Inc.. J.D. Watson: Advisory / Consultancy, The consultancy occured in the past: Boston Biomedical, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract